期刊發表

Communications Biology

Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer

Aug

09

2024

Biomedicines

CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci

Jul

08

2024

Drugs

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options

Sep

22

2023

Neoplasia

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer

Jan

31

2023

Hepatology

Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study

Sep

24

2022

Nature Communications

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Jun

24

2022

Signal Transduction and Targeted Therapy

Protein kinase CK2: a potential therapeutic target for diverse human diseases

Jul

20

2021

ASCO Meeting Library

Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.

Jan

12

2021